Engineers Gate Manager LP Purchases 247,037 Shares of The Cooper Companies, Inc. $COO

Engineers Gate Manager LP boosted its position in The Cooper Companies, Inc. (NASDAQ:COO) by 8,637.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 249,897 shares of the medical device company’s stock after buying an additional 247,037 shares during the quarter. Engineers Gate Manager LP’s holdings in Cooper Companies were worth $17,920,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in COO. Avalon Trust Co bought a new position in shares of Cooper Companies in the second quarter worth about $25,000. Root Financial Partners LLC increased its position in Cooper Companies by 104.5% in the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after buying an additional 162 shares during the period. SJS Investment Consulting Inc. lifted its holdings in shares of Cooper Companies by 107.5% during the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock worth $26,000 after buying an additional 187 shares during the last quarter. Elevation Wealth Partners LLC boosted its position in shares of Cooper Companies by 1,136.4% in the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 375 shares during the period. Finally, Continuum Advisory LLC acquired a new stake in shares of Cooper Companies in the second quarter worth $30,000. 24.39% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies reported fiscal Q3 non-GAAP EPS of $1.15, exceeding the $1.11-$1.12 analyst consensus. Revenue reached approximately $1.066 billion, while GAAP EPS was $2.24, helped by a $307.2 million discrete tax benefit from the favorable completion of a U.K. tax examination. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: Cash generation and capital returns were strong: free cash flow increased 66% to $273 million, and the company repurchased $339.1 million of stock during the quarter. The board also expanded its share-repurchase authorization from $2 billion to $3 billion. CooperCompanies Completes Strategic Review
• Neutral Sentiment: CooperSurgical revenue rose 2% on a reported basis and 3% organically, but CooperVision revenue was unchanged year over year. Overall quarterly revenue growth was only about 1% and fell short of the roughly $1.10 billion consensus estimate.
• Negative Sentiment: Management guided fiscal 2026 non-GAAP EPS to $4.51-$4.55, below the $4.63 analyst consensus, with revenue guidance of $4.229-$4.252 billion. Fourth-quarter EPS guidance of $1.05-$1.09 was also well below the approximately $1.20 expected by analysts. The Cooper Companies Q3 Earnings Metrics
• Negative Sentiment: The strategic review concluded that CooperSurgical will be retained because received offers were not sufficiently attractive. Investors may view this as a missed opportunity to unlock value, particularly amid valuation pressure from a new non-hormonal IUD competitor and fertility-related litigation costs. CooperCompanies Strategic Review and Buyback

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. UBS Group assumed coverage on shares of Cooper Companies in a research note on Tuesday, July 28th. They set a “neutral” rating and a $75.00 target price for the company. Wall Street Zen raised Cooper Companies from a “hold” rating to a “buy” rating in a research report on Sunday, June 21st. Needham & Company LLC lowered their price target on Cooper Companies from $101.00 to $86.00 and set a “buy” rating on the stock in a research note on Friday, June 5th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Cooper Companies in a report on Friday, September 4th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Cooper Companies from $80.00 to $71.00 and set a “neutral” rating for the company in a report on Friday, June 5th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Cooper Companies has an average rating of “Hold” and an average price target of $81.64.

Cooper Companies Stock Down 6.2%

NASDAQ:COO opened at $63.48 on Thursday. The company has a market cap of $12.38 billion, a price-to-earnings ratio of 53.80, a P/E/G ratio of 1.77 and a beta of 0.82. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.27. The stock’s fifty day moving average price is $72.42 and its two-hundred day moving average price is $70.02. The Cooper Companies, Inc. has a 52-week low of $58.89 and a 52-week high of $89.83.

Cooper Companies (NASDAQ:COO) last released its earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.12 by $0.03. The company had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The business’s revenue for the quarter was up .5% on a year-over-year basis. During the same period last year, the firm earned $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, analysts anticipate that The Cooper Companies, Inc. will post 4.63 EPS for the current year.

Cooper Companies announced that its board has approved a share repurchase plan on Wednesday, September 9th that authorizes the company to repurchase $3.00 billion in shares. This repurchase authorization authorizes the medical device company to buy up to 22.7% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.